Please find attached the financial results for the Quarter ended June 30, 2026
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 31 Jul 2026, 03:24 PM IST · BSE ID: edb3cbe2-2a6a-4991-885a-a4c40572ac13
View Original BSE Filing (PDF)
💡
In Simple Terms
Astec Lifesciences reported a loss in its latest quarterly financial results, with revenue also showing a decline.
🤖 AI Summary
- Astec Lifesciences approved Unaudited Financial Results (Standalone & Consolidated) for Quarter ended June 30, 2026.
- Consolidated Loss After Tax for Q1 FY27 was Rs. 1,870.73 lakhs.
- Consolidated Revenue From Operations for the quarter stood at Rs. 8,356.43 lakhs.
- Standalone Loss After Tax for Q1 FY27 reported as Rs. 1,873.84 lakhs.
- Statutory Auditors provided unmodified Limited Review Reports on the financial results.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue From Operations
8,356.43 Rs. in lakhs
-8.25%
Consolidated Loss After Tax
(1,870.73) Rs. in lakhs
43.49%
Consolidated Basic EPS
(8.40) Rs.
50.15%
Consolidated Net profit/(loss) margin(%)
-22.39%
38.21%
🏢 How This Affects the Company
Consolidated Revenue From Operations decreased to Rs. 8,356.43 lakhs in Q1 FY27 from Rs. 9,108.21 lakhs in Q1 FY26.
The company reported a consolidated loss after tax of Rs. 1,870.73 lakhs, compared to a loss of Rs. 3,302.69 lakhs in the prior comparable quarter. Total expenses increased to Rs. 10,302.99 lakhs in Q1 FY27 from Rs. 12,460.61 lakhs in Q1 FY26.
The Net profit/(loss) margin(%) remained negative at -22.39% consolidated, indicating continued operational challenges in profitability. Debt Equity ratio decreased to 0.98 consolidated, from 2.95 in the comparable prior year quarter.
👥 What This Means For Shareholders
✅
Action Required
No action required based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with the consolidated loss after tax attributable to owners of the Company being Rs. 1,871.74 lakhs.
🔍
Management Signal
The Board's approval of the unaudited results and noting of unmodified limited review reports indicates adherence to regulatory financial reporting requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — observe revenue and profitability trends.
Future disclosures on operational efficiency and cost management strategies.
Updates on Debt Equity ratio — track for sustained leverage reduction.
MEDIUM RISK
The company continues to report losses, and revenue from operations declined year-on-year, indicating ongoing business challenges.
💡 Investor Takeaway
Astec Lifesciences reported a consolidated loss after tax of Rs. 1,870.73 lakhs for Q1 FY27, an improvement from Rs. 3,302.69 lakhs in Q1 FY26. Consolidated Revenue From Operations decreased by 8.25% to Rs. 8,356.43 lakhs YoY.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Loss After Tax improved to Rs. 1,870.73 lakhs in Q1 FY27 from Rs. 3,302.69 lakhs in Q1 FY26.
- Consolidated Debt Equity ratio decreased to 0.98 in Q1 FY27 from 2.95 in Q1 FY26, indicating reduced leverage.
⚠️ Concerns
- Consolidated Revenue From Operations declined to Rs. 8,356.43 lakhs in Q1 FY27 from Rs. 9,108.21 lakhs in Q1 FY26, a decrease of 8.25%.
- Consolidated Net profit/(loss) margin(%) remained negative at -22.39% for Q1 FY27, indicating continued unprofitability.
📅 Company Track Record
A past filing on April 17, 2026, indicated a Board meeting scheduled for April 27, 2026, for FY26 audited financial results approval, prior to this Q1 FY27 results release.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Astec Lifesciences' consolidated revenue from operations for Q1 FY27?
Astec Lifesciences reported consolidated revenue from operations of Rs. 8,356.43 lakhs for the Quarter ended June 30, 2026.
What was Astec Lifesciences' consolidated loss after tax in Q1 FY27?
The consolidated loss after tax for Astec Lifesciences in Q1 FY27 was Rs. 1,870.73 lakhs, compared to a loss of Rs. 3,302.69 lakhs in Q1 FY26.
What was the consolidated basic earnings per share for Astec Lifesciences in Q1 FY27?
Consolidated basic earnings per share (non-annualized) for Astec Lifesciences was (8.40) Rs. for the Quarter ended June 30, 2026.
How did Astec Lifesciences' consolidated debt-to-equity ratio change in Q1 FY27?
The consolidated Debt Equity ratio for Astec Lifesciences decreased to 0.98 in Q1 FY27, compared to 2.95 in Q1 FY26.
Questions based on this BSE filing only. For information purposes.